08:24 AM EDT, 07/10/2024 (MT Newswires) -- Theratechnologies ( THTX ) , which commercializes two medicines that are part of HIV treatments, on Wednesday reported a swing to net income for the second quarter as revenue rose.

The pharmaceutical company recorded a US$1 million profit, compared with a loss of US$10 million, last year. Theratechnologies ( THTX ) credited the improvement to revenue growth and a tight control over expenses.

Consolidated revenue rose 26% to US$22 million, from US$17.5 million. The improvement was primarily due to EGRIFTA SV sales jumping 49.3% to US$16.2 million. However Trogarzo net sales fell to US$5.8 million, from US$7 million last year, the company said.

The company reaffirmed its full year 2024 revenue guidance of between US$87 and US$90 million. EGRIFTA SV remains its priority brand, with key performance metrics showing consistent growth and strong gross margins, Chief Executive Officer Paul Levesque added.